Johnson S V, Hoey L L, Vance-Bryan K
College of Pharmacy, University of Minnesota, Minneapolis, USA.
Pharmacotherapy. 1995 Sep-Oct;15(5):579-85. doi: 10.1002/j.1875-9114.1995.tb02866.x.
Increasing reports of vancomycin resistance have raised concerns about the future effectiveness of this drug in treatment of critically ill patients with gram-positive infections. Due to these concerns the Centers for Disease Control and Prevention (CDC) recently published criteria that delineate the prudent use of vancomycin. Using these criteria, we attempted to determine the appropriateness of vancomycin prescribing patterns at our institution. A retrospective chart review was performed for 135 hospitalized patients treated between May 1993 and April 1994. Inappropriate empiric vancomycin use was documented in 81 (60%) of these patients. When culture results were available, 28 (21%) patients inappropriately received the drug. Results of this study are similar to those of other studies of vancomycin use in hospitals based on non-CDC criteria. If CDC criteria are to have a positive impact on physicians' vancomycin prescribing patterns, significant educational efforts will be required.
万古霉素耐药性报告日益增多，这引发了人们对该药物未来治疗革兰氏阳性菌感染重症患者有效性的担忧。出于这些担忧，美国疾病控制与预防中心（CDC）最近发布了关于谨慎使用万古霉素的标准。依据这些标准，我们试图确定我院万古霉素处方模式的合理性。对1993年5月至1994年4月期间接受治疗的135例住院患者进行了回顾性病历审查。在这些患者中，有81例（60%）存在经验性使用万古霉素不当的记录。当有培养结果时，28例（21%）患者接受了不适当的该药物治疗。这项研究的结果与其他基于非CDC标准的医院万古霉素使用研究结果相似。若CDC标准要对医生的万古霉素处方模式产生积极影响，将需要进行大量的教育工作。
